The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Human Cytomegalovirus Envelope Glycoprotein B-Global Market Insights and Sales Trends 2025
Synopsis
The global Human Cytomegalovirus Envelope Glycoprotein B market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Human Cytomegalovirus Envelope Glycoprotein B in various end use industries. The expanding demands from the Infectious Disease, Oncology, Women's Health and Others, are propelling Human Cytomegalovirus Envelope Glycoprotein B market. CSJ-148, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CyMVectin segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Human Cytomegalovirus Envelope Glycoprotein B market, driven by demand from China, the second largest economy with some signs of stabilising, the Human Cytomegalovirus Envelope Glycoprotein B market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human Cytomegalovirus Envelope Glycoprotein B, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Human Cytomegalovirus Envelope Glycoprotein B market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Human Cytomegalovirus Envelope Glycoprotein B market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human Cytomegalovirus Envelope Glycoprotein B sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Human Cytomegalovirus Envelope Glycoprotein B covered in this report include Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, VBI Vaccine Inc and Vical Incorporated, etc.
The global Human Cytomegalovirus Envelope Glycoprotein B market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated
Global Human Cytomegalovirus Envelope Glycoprotein B market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human Cytomegalovirus Envelope Glycoprotein B market, Segment by Type:
CSJ-148
CyMVectin
TRL-345
PPCM
Cytomegalovirus Vaccine
Others
Global Human Cytomegalovirus Envelope Glycoprotein B market, by Application
Infectious Disease
Oncology
Women's Health
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Human Cytomegalovirus Envelope Glycoprotein B manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Human Cytomegalovirus Envelope Glycoprotein B in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The global Human Cytomegalovirus Envelope Glycoprotein B market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Human Cytomegalovirus Envelope Glycoprotein B in various end use industries. The expanding demands from the Infectious Disease, Oncology, Women's Health and Others, are propelling Human Cytomegalovirus Envelope Glycoprotein B market. CSJ-148, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CyMVectin segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Human Cytomegalovirus Envelope Glycoprotein B market, driven by demand from China, the second largest economy with some signs of stabilising, the Human Cytomegalovirus Envelope Glycoprotein B market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Human Cytomegalovirus Envelope Glycoprotein B, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Human Cytomegalovirus Envelope Glycoprotein B market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Human Cytomegalovirus Envelope Glycoprotein B market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Human Cytomegalovirus Envelope Glycoprotein B sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Human Cytomegalovirus Envelope Glycoprotein B covered in this report include Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, VBI Vaccine Inc and Vical Incorporated, etc.
The global Human Cytomegalovirus Envelope Glycoprotein B market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated
Global Human Cytomegalovirus Envelope Glycoprotein B market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Human Cytomegalovirus Envelope Glycoprotein B market, Segment by Type:
CSJ-148
CyMVectin
TRL-345
PPCM
Cytomegalovirus Vaccine
Others
Global Human Cytomegalovirus Envelope Glycoprotein B market, by Application
Infectious Disease
Oncology
Women's Health
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Human Cytomegalovirus Envelope Glycoprotein B manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Human Cytomegalovirus Envelope Glycoprotein B in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Human Cytomegalovirus Envelope Glycoprotein B Market Overview
1.1 Human Cytomegalovirus Envelope Glycoprotein B Product Overview
1.2 Human Cytomegalovirus Envelope Glycoprotein B Market Segment by Type
1.2.1 CSJ-148
1.2.2 CyMVectin
1.2.3 TRL-345
1.2.4 PPCM
1.2.5 Cytomegalovirus Vaccine
1.2.6 Others
1.3 Global Human Cytomegalovirus Envelope Glycoprotein B Market Size by Type
1.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market Size Overview by Type (2018-2029)
1.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Historic Market Size Review by Type (2018-2023)
1.3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Human Cytomegalovirus Envelope Glycoprotein B Sales Breakdown by Type (2018-2023)
1.4.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Human Cytomegalovirus Envelope Glycoprotein B Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales Breakdown by Type (2018-2023)
2 Global Human Cytomegalovirus Envelope Glycoprotein B Market Competition by Company
2.1 Global Top Players by Human Cytomegalovirus Envelope Glycoprotein B Sales (2018-2023)
2.2 Global Top Players by Human Cytomegalovirus Envelope Glycoprotein B Revenue (2018-2023)
2.3 Global Top Players by Human Cytomegalovirus Envelope Glycoprotein B Price (2018-2023)
2.4 Global Top Manufacturers Human Cytomegalovirus Envelope Glycoprotein B Manufacturing Base Distribution, Sales Area, Product Type
2.5 Human Cytomegalovirus Envelope Glycoprotein B Market Competitive Situation and Trends
2.5.1 Human Cytomegalovirus Envelope Glycoprotein B Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Human Cytomegalovirus Envelope Glycoprotein B Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Cytomegalovirus Envelope Glycoprotein B as of 2022)
2.7 Date of Key Manufacturers Enter into Human Cytomegalovirus Envelope Glycoprotein B Market
2.8 Key Manufacturers Human Cytomegalovirus Envelope Glycoprotein B Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Human Cytomegalovirus Envelope Glycoprotein B Status and Outlook by Region
3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Historic Market Size by Region
3.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales in Volume by Region (2018-2023)
3.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales in Value by Region (2018-2023)
3.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Forecasted Market Size by Region
3.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales in Volume by Region (2024-2029)
3.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales in Value by Region (2024-2029)
3.3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Human Cytomegalovirus Envelope Glycoprotein B by Application
4.1 Human Cytomegalovirus Envelope Glycoprotein B Market Segment by Application
4.1.1 Infectious Disease
4.1.2 Oncology
4.1.3 Women's Health
4.1.4 Others
4.2 Global Human Cytomegalovirus Envelope Glycoprotein B Market Size by Application
4.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market Size Overview by Application (2018-2029)
4.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Historic Market Size Review by Application (2018-2023)
4.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Human Cytomegalovirus Envelope Glycoprotein B Sales Breakdown by Application (2018-2023)
4.3.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Human Cytomegalovirus Envelope Glycoprotein B Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales Breakdown by Application (2018-2023)
5 North America Human Cytomegalovirus Envelope Glycoprotein B by Country
5.1 North America Human Cytomegalovirus Envelope Glycoprotein B Historic Market Size by Country
5.1.1 North America Human Cytomegalovirus Envelope Glycoprotein B Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Human Cytomegalovirus Envelope Glycoprotein B Sales in Volume by Country (2018-2023)
5.1.3 North America Human Cytomegalovirus Envelope Glycoprotein B Sales in Value by Country (2018-2023)
5.2 North America Human Cytomegalovirus Envelope Glycoprotein B Forecasted Market Size by Country
5.2.1 North America Human Cytomegalovirus Envelope Glycoprotein B Sales in Volume by Country (2024-2029)
5.2.2 North America Human Cytomegalovirus Envelope Glycoprotein B Sales in Value by Country (2024-2029)
6 Europe Human Cytomegalovirus Envelope Glycoprotein B by Country
6.1 Europe Human Cytomegalovirus Envelope Glycoprotein B Historic Market Size by Country
6.1.1 Europe Human Cytomegalovirus Envelope Glycoprotein B Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales in Volume by Country (2018-2023)
6.1.3 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales in Value by Country (2018-2023)
6.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Forecasted Market Size by Country
6.2.1 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales in Volume by Country (2024-2029)
6.2.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales in Value by Country (2024-2029)
7 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B by Region
7.1 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Historic Market Size by Region
7.1.1 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Forecasted Market Size by Region
7.2.1 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales in Value by Region (2024-2029)
8 Latin America Human Cytomegalovirus Envelope Glycoprotein B by Country
8.1 Latin America Human Cytomegalovirus Envelope Glycoprotein B Historic Market Size by Country
8.1.1 Latin America Human Cytomegalovirus Envelope Glycoprotein B Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Human Cytomegalovirus Envelope Glycoprotein B Sales in Volume by Country (2018-2023)
8.1.3 Latin America Human Cytomegalovirus Envelope Glycoprotein B Sales in Value by Country (2018-2023)
8.2 Latin America Human Cytomegalovirus Envelope Glycoprotein B Forecasted Market Size by Country
8.2.1 Latin America Human Cytomegalovirus Envelope Glycoprotein B Sales in Volume by Country (2024-2029)
8.2.2 Latin America Human Cytomegalovirus Envelope Glycoprotein B Sales in Value by Country (2024-2029)
9 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B by Country
9.1 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Historic Market Size by Country
9.1.1 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Forecasted Market Size by Country
9.2.1 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Astellas Pharma Inc.
10.1.1 Astellas Pharma Inc. Company Information
10.1.2 Astellas Pharma Inc. Introduction and Business Overview
10.1.3 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Products Offered
10.1.5 Astellas Pharma Inc. Recent Development
10.2 Trellis Bioscience, Inc.
10.2.1 Trellis Bioscience, Inc. Company Information
10.2.2 Trellis Bioscience, Inc. Introduction and Business Overview
10.2.3 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Products Offered
10.2.5 Trellis Bioscience, Inc. Recent Development
10.3 Vakzine Projekt Management GmbH
10.3.1 Vakzine Projekt Management GmbH Company Information
10.3.2 Vakzine Projekt Management GmbH Introduction and Business Overview
10.3.3 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Products Offered
10.3.5 Vakzine Projekt Management GmbH Recent Development
10.4 VBI Vaccine Inc
10.4.1 VBI Vaccine Inc Company Information
10.4.2 VBI Vaccine Inc Introduction and Business Overview
10.4.3 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2018-2023)
10.4.4 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Products Offered
10.4.5 VBI Vaccine Inc Recent Development
10.5 Vical Incorporated
10.5.1 Vical Incorporated Company Information
10.5.2 Vical Incorporated Introduction and Business Overview
10.5.3 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Products Offered
10.5.5 Vical Incorporated Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Human Cytomegalovirus Envelope Glycoprotein B Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Human Cytomegalovirus Envelope Glycoprotein B Industrial Chain Analysis
11.4 Human Cytomegalovirus Envelope Glycoprotein B Market Dynamics
11.4.1 Human Cytomegalovirus Envelope Glycoprotein B Industry Trends
11.4.2 Human Cytomegalovirus Envelope Glycoprotein B Market Drivers
11.4.3 Human Cytomegalovirus Envelope Glycoprotein B Market Challenges
11.4.4 Human Cytomegalovirus Envelope Glycoprotein B Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Human Cytomegalovirus Envelope Glycoprotein B Distributors
12.3 Human Cytomegalovirus Envelope Glycoprotein B Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
